全文获取类型
收费全文 | 4068篇 |
免费 | 263篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 156篇 |
妇产科学 | 52篇 |
基础医学 | 416篇 |
口腔科学 | 324篇 |
临床医学 | 282篇 |
内科学 | 1210篇 |
皮肤病学 | 125篇 |
神经病学 | 175篇 |
特种医学 | 173篇 |
外科学 | 546篇 |
综合类 | 37篇 |
一般理论 | 1篇 |
预防医学 | 244篇 |
眼科学 | 62篇 |
药学 | 229篇 |
1篇 | |
中国医学 | 11篇 |
肿瘤学 | 241篇 |
出版年
2023年 | 18篇 |
2022年 | 29篇 |
2021年 | 107篇 |
2020年 | 52篇 |
2019年 | 108篇 |
2018年 | 120篇 |
2017年 | 79篇 |
2016年 | 73篇 |
2015年 | 88篇 |
2014年 | 112篇 |
2013年 | 151篇 |
2012年 | 173篇 |
2011年 | 241篇 |
2010年 | 154篇 |
2009年 | 159篇 |
2008年 | 159篇 |
2007年 | 219篇 |
2006年 | 182篇 |
2005年 | 198篇 |
2004年 | 190篇 |
2003年 | 177篇 |
2002年 | 174篇 |
2001年 | 150篇 |
2000年 | 181篇 |
1999年 | 127篇 |
1998年 | 82篇 |
1997年 | 78篇 |
1996年 | 65篇 |
1995年 | 31篇 |
1994年 | 47篇 |
1993年 | 34篇 |
1992年 | 72篇 |
1991年 | 65篇 |
1990年 | 67篇 |
1989年 | 69篇 |
1988年 | 57篇 |
1987年 | 35篇 |
1986年 | 31篇 |
1985年 | 24篇 |
1984年 | 20篇 |
1983年 | 23篇 |
1982年 | 14篇 |
1981年 | 14篇 |
1980年 | 9篇 |
1979年 | 7篇 |
1978年 | 10篇 |
1975年 | 8篇 |
1970年 | 7篇 |
1968年 | 7篇 |
1966年 | 5篇 |
排序方式: 共有4341条查询结果,搜索用时 468 毫秒
111.
Valcárcel D Martino R Sureda A Canals C Altés A Briones J Sanz MA Parody R Constans M Villela SL Brunet S Sierra J 《European journal of haematology》2005,74(2):144-151
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)-compatible sibling donors is a potential curative treatment for hematological and non-hematological malignancies. Nevertheless, high mortality rates may be associated with this therapy, especially in older patients, those with other comorbidities or who receive a second HSCT. PATIENTS AND METHODS: We analyzed the factors associated with transplant-related mortality (TRM) and overall survival in 157 consecutive adult patients (104 males and 53 females) who received a HSCT [29 bone marrow (BM) transplantation and 128 peripheral blood (PB) transplantation] from a HLA-identical sibling between January 1995 and March 2002 in our institution. One hundred patients received a standard conditioning prior to HSCT (STAND) and 57 patients received a reduced-intensity conditioning (RIC) HSCT. Fifty-eight patients were in an early phase at transplant and 99 in a non-early phase. Median age was 46 yr (16-66), and 90 patients (57%) were >45 yr of age. RESULTS: Patients in the RIC group were older than those in the STAND group, and had a higher proportion of non-early disease phases including a prior autologous HSCT in 39%. Median follow-up for survivors was 28 and 15 months in the STAND and RIC groups (P < 0,001), respectively. Cumulative incidence of TRM at 2 yr was 30% [95% confidence interval (CI) 22-41%] for the STAND group and 22% (95% CI 13-37%) for the RIC group [non-significant (NS)]. Factors associated with a higher TRM in multivariate analysis were: STAND vs. RIC conditioning regimen [relative risk (RR) 5.4; 95% CI 2.3-12.8; P < 0.001]; age > or =45 yr vs. <45 yr (RR 5; 95% CI 2.4-10.8, P < 0.001); second vs. first HSCT (RR 2.8, 95% CI 1.3-6.3, P = 0.01) and non-T-cell-depleted vs. T-cell-depleted graft (RR 2.7, 95% CI 1.3-5.8, P = 0.009). Overall survival (OS) at 2 yr was 52.5 +/- 10.4% for STAND group and 59 +/- 16.8% in RIC group. Factors associated with poorer OS in multivariate analysis were: STAND vs. RIC conditioning regimen (RR 3.4, 95% CI 1.7-6.9, P = 0.001); age > or =45 vs <45 yr (RR 2.5, 95% CI 1.4-4.5, P = 0.002) and diagnosis [other than chronic myeloid leukemia (CML) vs. CML] (RR 2.6, 95% CI 1.2-5.7 P = 0.02). CONCLUSIONS: Our results indicate that the introduction of RIC allogeneic HSCT for patients at high risk for TRM (advanced age, prior HSCT and non-T-cell depletion) leads to a reduction in the TRM and improvement in the OS. 相似文献
112.
113.
114.
115.
A L de Weck M L Sanz 《Journal of investigational allergology & clinical immunology》2004,14(4):253-273
Specific diagnosis of immediate type allergies, such as rhinoconjunctivis, asthma, urticaria/angioedema and anaphylaxis, particularly when IgE-mediated, traditionally rests on prick and/or intradermal skin tests and, since about 30 years, on the determination of allergen specific IgEs. Some cellular tests, i.e. tests determining the reactivity of blood cells in vitro, particularly basophils, to allergens, have been available for many years. The determination of histamine release has been widely used in allergy pathophysiological research but its routine application in allergy diagnosis has been restricted to few groups. Basophil degranulation, as determined by microscopic examination, was promoted by some groups in the 1980's but has been largely abandoned since around 10 years ago; an alternative cellular test, based on the determination of sulfidoleukotrienes (LTC4, LTD4, LTE4) produced by IL-3 primed basophils stimulated by allergens in vitro, has been proposed. This test became available commercially in 1993 under the name of CAST (Bühlmann Laboratories, Allschwil, Switzerland). The CAST assay has been used in allergy diagnosis in a variety of indications, such as inhalation allergies, allergies to insect venoms, foods, occupational allergens and various drugs. A large number of reports on CAST diagnostic value, however, have been anecdotal. A meta-analysis of validated and well controlled studies encompasses 37 studies, 1614 patients and 1145 controls. This should definitely establish the value of this diagnostic test, particularly in instances where other in vitro or in vivo diagnostic tests are not reliable, such as food or drug allergies, as well as in non-IgE-mediated immediate hypersensitivity reactions. However, a number of questions about the CAST diagnostic assay are still open or have not been systematically explored. This may explain, in addition to the practical limitations inherent to all allergy cellular tests, why CAST has not yet become a very widely used assay worldwide, having gained broad acceptance in some countries but not in others. 相似文献
116.
117.
Castillo Laita JA De Benito Fernández J Escribano Montaner A Fernández Benítez M García de la Rubia S Garde Garde J García-Marcos L González Díaz C Ibero Iborra M Navarro Merino M Pardos Martínez C Pellegrini Belinchon J Sánchez Jiménez J Sanz Ortega J Villa Asensi JR 《Allergologia et immunopathologia》2008,36(1):31-52
118.
J. F. San Miguel M. Gonzáalez A. Gascón Ma J. Moro J. M. Hernáandez F. Ortega R. Jimenez L. Guerras M. Romero F. Casanova M. A. Sanz J. Sáanchez J. A. Portero A. Orfao 《British journal of haematology》1991,77(2):185-190
In 112 untreated myeloma patients we have analysed the immunophenotype of plasma cells both by immunofluorescence (IF) and immunocytochemistry (APAAP). Both techniques yielded similar results pointing to an important degree of heterogeneity in antigenic expression not only between different patients but also within the same patient. The expression of CD38 and Han-PC1 antigens (Ags) was almost constant (greater than 90% positive cases), while CD9 was detected in 66% of the cases. On the other hand, less than one third of patients were positive for CD10, CD20 and HLA-DR and generally with a weak expression (less than 30% positive plasma cells). In occasional cases plasma cells were weakly positive for the myelomonocytic markers CD13 (9%), CD15 (25%) and CD14 (6%). The possibility that this heterogeneity might be the result of different stages of differentiation of the neoplastic clone is suggested both by the positive correlation in the expression of some of these antigens (CD10, CD9, CD20, HLA-DR) and by the relationship between CD10 and myeloid antigens with immature plasma cell morphology. Finally, the cALLA antigen does not seem to be of significant value in predicting survival. Moreover, none of the other markers explored showed a clear influence in the course of the disease, although the tendency towards a lower survival found for the CD20+ cases as well as the association of the expression of some antigens and advanced clinical stage, may warrant further studies in a larger series of patients. 相似文献
119.
120.
Sandra Rayego‐Mateos Jose Luis Morgado‐Pascual Ana Belen Sanz Adrian Mario Ramos Satoru Eguchi Daniel Batlle Janos Pato Gyorgy Keri Jesus Egido Alberto Ortiz Marta Ruiz‐Ortega 《The Journal of pathology》2013,231(4):480-494
TWEAK, a member of the TNF superfamily, binds to the Fn14 receptor, eliciting biological responses. EGFR signalling is involved in experimental renal injury. Our aim was to investigate the relationship between TWEAK and EGFR in the kidney. Systemic TWEAK administration into C57BL/6 mice increased renal EGFR phosphorylation, mainly in tubular epithelial cells. In vitro, in these cells TWEAK phosphorylated EGFR via Fn14 binding, ADAM17 activation and subsequent release of the EGFR ligands HB‐EGF and TGFα. In vivo the EGFR kinase inhibitor Erlotinib inhibited TWEAK‐induced renal EGFR activation and downstream signalling, including ERK activation, up‐regulation of proinflammatory factors and inflammatory cell infiltration. Moreover, the ADAM17 inhibitor WTACE‐2 also prevented those TWEAK‐induced renal effects. In vitro TWEAK induction of proinflammatory factors was prevented by EGFR, ERK or ADAM17 inhibition. In contrast, EGFR transactivation did not modify TWEAK‐mediated NF‐κB activation. Our data suggest that TWEAK transactivates EGFR in the kidney, leading to modulation of downstream effects, including ERK activation and inflammation, and suggest that inhibition of EGFR signalling could be a novel therapeutic tool for renal inflammation. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 相似文献